[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7155 Introduced in House (IH)]

<DOC>






118th CONGRESS
  2d Session
                                H. R. 7155

      To provide for the establishment, within the Food and Drug 
Administration, of an Abraham Accords Bureau to promote and facilitate 
 cooperation between the Food and Drug Administration and entities in 
 Abraham Accords countries wishing to work with the agency in order to 
develop and sell products in the United States, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 31, 2024

  Mrs. Harshbarger (for herself, Mr. Vargas, Mr. Weber of Texas, Mr. 
Peters, Mr. Harris, Mr. Levin, and Mr. Allen) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
      To provide for the establishment, within the Food and Drug 
Administration, of an Abraham Accords Bureau to promote and facilitate 
 cooperation between the Food and Drug Administration and entities in 
 Abraham Accords countries wishing to work with the agency in order to 
develop and sell products in the United States, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``United States-Abraham Accords 
Cooperation and Security Act of 2024''.

SEC. 2. ESTABLISHMENT OF ABRAHAM ACCORDS BUREAU WITHIN FOOD AND DRUG 
              ADMINISTRATION.

    (a) In General.--Chapter X of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 391 et seq.) is amended by adding at the end the 
following:

``SEC. 1015. ABRAHAM ACCORDS BUREAU.

    ``(a) In General.--The Secretary, acting through the Commissioner 
of Food and Drugs, shall establish within the Food and Drug 
Administration a bureau, to be known as the Abraham Accords Bureau, to 
be headed by a director.
    ``(b) Offices.--Not later than one year after the date of enactment 
of this section, the Secretary shall--
            ``(1) in consultation with the governments of Abraham 
        Accords countries--
                    ``(A) select the locations of one or more offices 
                of the Abraham Accords Bureau in one or more Abraham 
                Accords countries; and
                    ``(B) establish each such office; and
            ``(2) assign to each such office such personnel of the Food 
        and Drug Administration as the Secretary determines necessary 
        to carry out the functions of the office.
    ``(c) Duties.--The Secretary, acting through the Director of the 
Abraham Accords Bureau, shall--
            ``(1) not later than 90 days after all offices of the 
        Abraham Accords Bureau are established--
                    ``(A) develop a list of essential medical, 
                biomedical, and life sciences products, the key raw 
                pharmaceutical ingredients of such products, and the 
                active pharmaceutical ingredients of such products, 
                that are primarily manufactured in a covered country;
                    ``(B) develop a list of medical, biomedical, and 
                life sciences facilities and entities in Abraham Accord 
                countries that can engage with offices of the Abraham 
                Accords Bureau to bolster the United States' health 
                care and medical supply needs; and
                    ``(C) submit such lists to the Congress;
            ``(2) not less than every 3 years thereafter, update the 
        lists under paragraph (1) and submit the updated lists to the 
        Congress;
            ``(3) consult with parties in Abraham Accords countries on 
        good manufacturing practices and other issues relevant to 
        manufacturing medical products that are regulated by the Food 
        and Drug Administration;
            ``(4) facilitate interactions between the Food and Drug 
        Administration and interested parties in Abraham Accords 
        countries, including by sharing relevant information regarding 
        United States regulatory pathways with such parties;
            ``(5) offer technical assistance on manufacturing drugs and 
        devices to interested parties in Abraham Accords countries; and
            ``(6) carry out other functions and activities as the 
        Secretary determines to be necessary to carry out this section.
    ``(d) Limitation.--Notwithstanding any other provision of this 
section, this section does not authorize any assistance to any entity 
in an Abrahams Accords country that, for purposes of manufacturing, 
uses any ingredient or product that is produced or manufactured in a 
covered country.
    ``(e) Definitions.--In this section:
            ``(1) The term `Abraham Accords country' means a country 
        identified by the Department of State as having signed the 
        Abraham Accords Declaration.
            ``(2) The term `covered country' means a country--
                    ``(A) designated as a country of particular concern 
                for religious freedom under section 402(b)(1)(A)(ii) of 
                the International Religious Freedom Act of 1998; or
                    ``(B) the government of which engages in a 
                consistent pattern of gross violations of 
                internationally recognized human rights, as defined in 
                section 502B(d)(1) of the Foreign Assistance Act of 
                1961.
            ``(3) The term `essential medical products' shall have such 
        definition as the Secretary may determine for purposes of this 
        section.
            ``(4) The term `primarily manufactured in a covered 
        country' means--
                    ``(A) manufactured in a covered country in final 
                form; or
                    ``(B) containing any active pharmaceutical 
                ingredient or excipient that was manufactured in a 
                covered country.''.
    (b) Report to Congress.--Not later than 3 years after the date of 
enactment of this Act, the Secretary of Health and Human Services shall 
submit to the Congress a report on the Abraham Accords Bureau, 
including--
            (1) an evaluation of--
                    (A) how each office of the Bureau has advanced 
                progress toward shifting United States supply chains of 
                essential medical products from covered countries to 
                Abraham Accords countries (as such terms are defined in 
                section 1015 of the Federal Food, Drug, and Cosmetic 
                Act, as added by subsection (a)); and
                    (B) the effectiveness of the activities carried out 
                pursuant to section 1015(c) of the Federal Food, Drug, 
                and Cosmetic Act, as added by subsection (a); and
            (2) recommendations for increasing and improving 
        coordination between the Food and Drug Administration and 
        entities in Abraham Accords countries (as such term is defined 
        in section 1015 of the Federal Food, Drug, and Cosmetic Act, as 
        added by subsection (a)).
                                 <all>